2nd Quarter - Report — TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC (2025)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

TEVA PHARMACEUTICALS USA, INC.

Client

TEVA PHARMACEUTICALS USA INC

Income

—

Expenses

$1,390,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Jul 17, 2025	$1,390,000	Replaced
2nd Quarter - Amendment	Sep 4, 2025	$1,390,000	Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., identified on Registration (LD-1) as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

Lobbyist	Covered position, as disclosed
MICHAEL BRZICA	—
BEENA S PATEL	—
COLMAN BRENDAN RAGAN	—

Contacted: Homeland Security, Dept of (DHS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Tariff (miscellaneous tariff bills) TAR

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., identified on Registration (LD-1), as the indirect parent of Teva Pharmaceuticals USA, Inc., has an interest in the issues listed.

Lobbyist	Covered position, as disclosed
MICHAEL BRZICA	—
BEENA S PATEL	—

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Food & Drug Administration (FDA); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); SENATE

Bills named: S.J.Res. 37 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.